M. Nooij

4.0k total citations
45 papers, 2.9k citations indexed

About

M. Nooij is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, M. Nooij has authored 45 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Genetics. Recurrent topics in M. Nooij's work include Cancer Treatment and Pharmacology (12 papers), Sarcoma Diagnosis and Treatment (12 papers) and Estrogen and related hormone effects (12 papers). M. Nooij is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Sarcoma Diagnosis and Treatment (12 papers) and Estrogen and related hormone effects (12 papers). M. Nooij collaborates with scholars based in Netherlands, Belgium and United Kingdom. M. Nooij's co-authors include L.V.A.M. Beex, M. van Glabbeke, Martine Piccart, Barbara Uscinska, Robert Paridaens, Pancras C.W. Hogendoorn, Anne M. Stiggelbout, S.J.T. Jansen, David Cameron and Alan Craft and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

M. Nooij

45 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Nooij Netherlands	29	1.4k	1.3k	778	612	446	45	2.9k
V. Bramwell Canada	27	2.0k 1.4×	1.6k 1.3×	784 1.0×	257 0.4×	436 1.0×	67	3.5k
Ola Bratt Sweden	35	1.1k 0.8×	2.8k 2.2×	434 0.6×	383 0.6×	581 1.3×	156	4.0k
H. Anderson Sweden	28	1.4k 1.0×	603 0.5×	582 0.7×	482 0.8×	254 0.6×	51	2.8k
Rebecca A. Nelson United States	36	1.2k 0.9×	1.3k 1.1×	623 0.8×	293 0.5×	804 1.8×	124	3.5k
Richard Tozer Canada	27	1.2k 0.9×	994 0.8×	245 0.3×	260 0.4×	847 1.9×	52	3.0k
Adnan Ezzat Saudi Arabia	26	1.4k 1.0×	667 0.5×	548 0.7×	164 0.3×	399 0.9×	83	3.2k
Alexander Paterson Canada	34	4.0k 2.9×	1.1k 0.9×	858 1.1×	467 0.8×	691 1.5×	104	5.1k
Alan P. Lyss United States	27	1.2k 0.9×	879 0.7×	327 0.4×	189 0.3×	374 0.8×	66	2.7k
Heather Lin United States	40	2.2k 1.5×	1.6k 1.3×	1.0k 1.3×	232 0.4×	1.3k 2.8×	173	4.9k
Jean‐Emmanuel Kurtz France	28	891 0.6×	1.1k 0.9×	248 0.3×	116 0.2×	420 0.9×	113	2.6k

Countries citing papers authored by M. Nooij

Since Specialization

Citations

This map shows the geographic impact of M. Nooij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Nooij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Nooij more than expected).

Fields of papers citing papers by M. Nooij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Nooij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Nooij. The network helps show where M. Nooij may publish in the future.

Co-authorship network of co-authors of M. Nooij

This figure shows the co-authorship network connecting the top 25 collaborators of M. Nooij. A scholar is included among the top collaborators of M. Nooij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Nooij. M. Nooij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gelderblom, Hans, Rachel C. Jinks, Matthew R. Sydes, et al.. (2011). Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. European Journal of Cancer. 47(6). 895–902. 104 indexed citations

McTiernan, Anne, Rachel C. Jinks, Matthew R. Sydes, et al.. (2011). Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup. European Journal of Cancer. 48(5). 703–712. 40 indexed citations

Jansen-Landheer, M.L.E.A., Pieta Krijnen, E.M. Noordijk, et al.. (2009). Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: A population-based study. European Journal of Surgical Oncology. 35(12). 1326–1332. 36 indexed citations

Paridaens, Robert, Luc Dirix, L.V.A.M. Beex, et al.. (2008). Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology. 26(30). 4883–4890. 228 indexed citations

Gast, Marie‐Christine W., Harm van Tinteren, M. Bontenbal, et al.. (2008). Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer. 8(1). 389–389. 24 indexed citations

Lewis, Ian, M. Nooij, Jeremy Whelan, et al.. (2007). Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup. JNCI Journal of the National Cancer Institute. 99(2). 112–128. 272 indexed citations

Hannemann, Juliane, Petra Kristel, Harm van Tinteren, et al.. (2006). Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy. British Journal of Cancer. 95(10). 1334–1341. 54 indexed citations

Beex, L.V.A.M., Carsten Rose, H.T. Mouridsen, et al.. (2006). Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863). European Journal of Cancer. 42(18). 3178–3185. 10 indexed citations

Nooij, M., Jeremy Whelan, V. Bramwell, et al.. (2004). Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. European Journal of Cancer. 41(2). 225–230. 39 indexed citations

10.

Paridaens, Robert, Luc Dirix, Caroline Lohrisch, et al.. (2003). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology. 14(9). 1391–1398. 172 indexed citations

11.

Anninga, Jakob, Marc J. van de Vijver, Anne‐Marie Cleton-Jansen, et al.. (2003). Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. European Journal of Cancer. 40(7). 963–970. 57 indexed citations

12.

Awada, Ahmad, Laura Biganzoli, Tanja Čufer, et al.. (2002). An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer. 38(6). 773–778. 6 indexed citations

13.

Wijk, F.H. van, C. Lhommé, Giorgio Bolis, et al.. (2002). Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. European Journal of Cancer. 39(1). 78–85. 27 indexed citations

14.

Wagenaar, Hendrik, N. Colombo, Ignace Vergote, et al.. (2001). Bleomycin, Methotrexate, and CCNU in Locally Advanced or Recurrent, Inoperable, Squamous-Cell Carcinoma of the Vulva: An EORTC Gynaecological Cancer Cooperative Group Study. Gynecologic Oncology. 81(3). 348–354. 57 indexed citations

15.

Jansen, S.J.T., J. Kievit, M. Nooij, et al.. (2001). Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?. British Journal of Cancer. 84(12). 1577–1585. 73 indexed citations

16.

Jansen, S.J.T., Anne M. Stiggelbout, M. Nooij, & J. Kievit. (2000). The effect of individually assessed preference weights on the relationship between holistic utilities and nonpreference-based assessment. Quality of Life Research. 9(5). 541–557. 17 indexed citations

17.

Voûte, P.A., R L Souhami, M. Nooij, et al.. (1999). A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. Annals of Oncology. 10(10). 1211–1218. 38 indexed citations

18.

Paridaens, R., M. Nooij, Jan G.M. Klijn, et al.. (1998). Vorozole (Rivizor???): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Anti-Cancer Drugs. 9(1). 29–35. 4 indexed citations

19.

Guastalla, Jean Paul, Jan B. Vermorken, J. Wils, et al.. (1994). Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy—a phase II study of the EORTC gynaecological cancer cooperative group. European Journal of Cancer. 30(1). 45–49. 15 indexed citations

20.

Engelsman, E, R.D. Rubens, J. Wildiers, et al.. (1991). “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. European Journal of Cancer and Clinical Oncology. 27(8). 966–970. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact